Prevalence and characteristics of gastric remnant cancer: A systematic review and meta-analysis

Mak, Tsz Kin; Guan, Bingsheng; Peng, Juzheng; Chong, Tsz Hong; Wang, Cunchuan; Huang, Shifang; Yang, Jingge

doi:10.1016/j.asjsur.2020.03.012

Cited by 28 publications

(23 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GMNECs are a rare type of malignant tumor in the digestive system[ 6 ]. Mak et al [ 7 ] reported that the occurrence rate of GRC ranged from 0.9%–12.9%, and the pooled prevalence of GRC was 2.6%. GMNEC is a particularly rare type that exhibits aggressive behavior and a poor prognosis, and it accounts for 0.1%–0.6% of all gastric carcinomas[ 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…A lower TNM stage is associated with a higher 5-year survival rate[ 20 ]. However, Mak et al [ 7 ] reported that the 5-year survival rate of GRC patients with primary gastric carcinoma was higher than that for patients with benign diseases. The present data indicate that high-grade GMNECs appear to lead to a better prognosis than pure neuroendocrine carcinomas, whereas the overall prognosis of intermediate-grade MNECs is poorly understood[ 5 , 6 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mixed neuroendocrine carcinoma of the gastric stump: A case report

Zhu

Zhang

Sun

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Gastric stump cancer, also known as gastric remnant cancer (GRC), is one of the main complications of postgastrectomy syndrome, which usually occurs following Billroth II reconstruction. The predominant histological subtype of GRC is adenocarcinoma, whereas neuroendocrine carcinoma is relatively rare. In particular, there are few recently reported cases of mixed neuroendocrine carcinoma (MNEC) in the English literature. Here, we present an extremely rare case of MNEC of the gastric stump. CASE SUMMARY A 59-year-old patient presented to our department owing to chronic constipation. He had undergone subtotal gastric resection 35 years prior to admission because of benign peptic ulcer. After admission, the patient underwent several tests, and gastroendoscopy showed evidence of Billroth II gastrectomy and local thickening of the gastric stump mucosa at the gastrojejunostomy site, with bile reflux; pathological biopsy revealed adenocarcinoma. He was then diagnosed with GRC and underwent total gastrectomy, D2 Lymphadenectomy, and esophagojejunal Roux-en-Y reconstruction. Histopathological examination of the specimen identified MNEC comprising MNEC (60%), adenocarcinoma (30%), and squamous cell carcinoma (10%). Postoperative adjuvant chemotherapy was initiated on September 17, 2020. Taxol plus cisplatin was administered for only one cycle because of severe liver function damage, and the regimen was changed to etoposide plus cisplatin on October 10, 2020 for five cycles. The patient recovered, with no recurrence after 6 mo of follow-up. CONCLUSION Gastric MNECs (GMNECs) is a rare type of GRC. This study presented the unusual occurrence of GMNEC in the gastric stump. This case will contribute to improvements in our understanding of the carcinogenesis, biology, pathology, and behavior of GMNEC and GRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Mixed neuroendocrine carcinoma of the gastric stump: A case report

Zhu

Zhang

Sun

et al. 2021

WJCC

View full text Add to dashboard Cite

show abstract

“…Gastric cancer (GC) remains one of the most commonly diagnosed cancers of human beings with high incidence and high-grade malignancy [ 1 ]. Since its insidious onset, GC usually gets dropped, and most GC patients are diagnosed at an advanced stage for that tumor metastasis is common [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

SLC6A14 Depletion Contributes to Amino Acid Starvation to Suppress EMT-Induced Metastasis in Gastric Cancer by Perturbing the PI3K/AKT/mTORC1 Pathway

Guo

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Metastasis is the main obstacle for the treatment of gastric cancer (GC), leading to low survival rate and adverse outcomes in CG patients. SLC6A14, a general amino acid transporter, can import all the essential amino acids in a manner dependent on the NaCl-generated osmotic gradients. Herein, we constructed GC cell sublines with high (SGC7901-M and MKN28-M) and low (MKN28-NM and SGC7901-NM) metastatic ability. Putative functional genes advancing GC metastasis were identified using mRNA microarray analysis and High-Content Screening. In particular, most significant change with a dampening trend in the migration potentiality of GC cells emerged after SLC6A14 gene was silenced. SLC6A14 expression was positively correlated with the migrated capability of different GC cell lines, and SLC6A14 was also constitutively expressed in GC patients with venous or lymphatic invasion, lymph node, or distant metastasis and poor prognosis, thus prompting SLC6A14 as a nonnegligible presence in supporting GC migration and invasion. Consistently, SLC6A14 depletion drastically depressed GC metastasis in vitro and in vivo. Most importantly, pharmacological blockade and gene silence of SLC6A14 both restricted epithelial-mesenchymal transition- (EMT-) driven GC metastasis, in which attenuated activation of the PI3K/AKT/mTORC1 pathway caused by amino acid starvation was involved. In summary, it is conceivable that targeting SLC6A14 has a tremendous promising for the treatment of metastatic GC.

show abstract

“…[7][8][9][10] This could change the importance of LN dissection and the prognostic influence of LN dissection for RGC. 3,11,12 For early RGC, is it justifiable to use current criteria of additional gastrectomy after endoscopic submucosal dissection (ESD) [13][14][15] ? For advanced RGC, is it really expected to perform splenectomy and jejunal LN dissection?…”

Section: Introductionmentioning

confidence: 99%

Evaluating the optimal treatment strategy for early and advanced remnant gastric cancer

Hayashi

Fujita

Matsushita

2022

ANZ Journal of Surgery

View full text Add to dashboard Cite

Background This study assessed lymph node metastasis characteristics to investigate the optimal treatment strategy for early and advanced remnant gastric cancer (RGC). Methods Cases of completion gastrectomy for RGC were enrolled. The frequency of lymph node metastasis was investigated, and risk factors for metastasis were identified. The clinical significance of completion gastrectomy in early remnant gastric carcinoma cases was also examined. In advanced cases, 3‐year survival was analysed to investigate the prognostic importance of lymph node dissection and splenectomy. Results Seventy‐nine patients were included. Lymphatic invasion and pathological tumour depth were identified as risk factors for lymph node metastasis. There was no metastasis in the pT1 cases. In advanced cases, the incidence of lymph node #10 and jejunal lymph node metastasis was 8.3–10.0% and 17.6%, respectively. Prognosis was found to be unrelated with splenectomy. Conclusions Lymphatic invasion and pathological T status were identified as risk factors for LN metastasis in RGC. Additional gastrectomy after ESD might not be mandatory for early RGC cases. For advanced RGC cases, splenectomy might not improve patient prognosis, however, lymph node dissection of jejunal and #10 lymph nodes should be considered due to its high incidence of metastasis.

show abstract

Prevalence and characteristics of gastric remnant cancer: A systematic review and meta-analysis

Cited by 28 publications

References 34 publications

Mixed neuroendocrine carcinoma of the gastric stump: A case report

Mixed neuroendocrine carcinoma of the gastric stump: A case report

SLC6A14 Depletion Contributes to Amino Acid Starvation to Suppress EMT-Induced Metastasis in Gastric Cancer by Perturbing the PI3K/AKT/mTORC1 Pathway

Evaluating the optimal treatment strategy for early and advanced remnant gastric cancer

Contact Info

Product

Resources

About